Common use of SCREENING PROGRAM Clause in Contracts

SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE B. Extension Assay *** *** FTE C. Neurotoxicity *** *** FTE D. Specificity *** *** FTE PPI will make available *** FTE's to the Screening Program immediately following the Effective Date. These FTE's will either be new hires or redeployments of existing personnel. PPI anticipates that it will be evaluating BI compounds in assays A-D within 6 weeks of first receiving compounds from BI. All Applicable data will be supplied to BI in PC compatible form (e.g. ASCI II or Excel files). All BI compounds will be handled or disposed of in accordance with BI's written instructions. A. Nucleation Assay: A rapid high-throughput primary screen The nucleation assay *** Approximately 13 lines omitted *** B. Extension Assay: *** The extension assay *** Approximately 6 lines omitted *** C. Neurotoxicity Assay: in vitro Cellular Efficacy *** Approximately 10 lines omitted *** D. Amyloid Specificity Assays *** Approximately 9 lines omitted ***